Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.

Miao-Zhen QiuDo-Youn OhKen KatoTobias ArkenauJosep TaberneroMarcia Cruz CorreaAnastasia V ZiminaYuxian BaiJianhua ShiKeun-Wook LeeJufeng WangElena PoddubskayaHongming PanSun Young RhaRuixing ZhangHidekazu HiranoDavid SpigelKensei YamaguchiYee ChaoLucjan WyrwiczUmut DiselRoberto Pazo CidLorenzo FornaroLudovic EvesqueHongwei WangYaling XuJiang LiTao ShengSilu YangLiyun LiMarkus MoehlerRui-Hua Xunull null

Published in: BMJ (Clinical research ed.) (2024)

ClinicalTrials.gov NCT03777657.

Keyphrases

double blind
placebo controlled
locally advanced
clinical trial
phase iii
squamous cell carcinoma
rectal cancer
study protocol
open label
phase ii
radiation therapy
chemotherapy induced